Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7913MR)

This product GTTS-WQ7913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7913MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7673MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ5607MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ10927MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ4339MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2049MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ4659MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ11926MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW